On Dec. 21, 2018, the U.S. Food and Drug Administration (FDA) approved a new combination hexavalent vaccine (Vaxelis) that includes antigens for six different diseases: diphtheria, tetanus, pertussis, hepatitis B, poliomyelitis and invasive haemophilus influenza type B. Combination vaccines have been created by manufacturers to purportedly reduce the number of shots a child must receive to be in compliance with government recommended childhood vaccine schedules and to simplify ordering, transport and storage of vaccines. Drawbacks to the multivalent vaccines include a higher risk of pain and swelling at the injection site and, and for Merck’s MMRV (mumps, measles, rubella, varicella) vaccine in particular, a higher incidence of febrile seizures in children under age four. The product manufacturer package insert for the new hexavalent vaccine states that Vaxelis is contraindicated in children with a history of severe allergic reaction to any of the ingredients of the vaccine, or to any “other diphtheria toxoid, tetanus toxoid, pertussis-containing vaccine, inactivated poliovirus vaccine, hepatitis B vaccine, or H. influenzae type b vaccine.”
It appears that the pharmaceutical industry is trying to cram as many vaccines as humanly possible into one syringe and advertise these combination vaccines as safe and effective. In reality, however, a growing number of medical professionals are concerned that administering too many vaccinations to an infant at one time increases their chance of suffering an adverse reaction. This is especially the case for combination vaccinations, and it appears that the fears of medical professionals are justified, because, over the years, history has painted a very disturbing picture.